Multiple Sclerosis (MS)

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/87

encourage image

There's no tags or description

Looks like no tags are added yet.

88 Terms

1
New cards

Multiple Sclerosis (MS)

Characterized by CNS demyelination and axonal damage, and is thought to be a chronic inflammatory and neurodegenerative disorder

2
New cards

high-dose

- IV/PO Methylprednisolone

- The onset of clinical response is typically within 3-5 days

Exacerbations or relapses of MS can be disabling and are treated with ___-dose glucocorticoids

3
New cards

lesions or plaques

- primarily found in the brain, spinal cord, and optic nerves

Demyelization leads to the formation of the MS ____

4
New cards

- Numbness, tingling

- Walking difficulty

- Vision problems

- Weakness

- Dizziness

- Depression

- Muscle spasms

- Bladder dysfunction

- Bowel dysfunction

- Pain

- Cognitive dysfunction

Typical clinical presentation of MS

5
New cards

≥24 hours

A relapse or clinical attack usually lasts ≥____ hours.

6
New cards

- Optic neuritis: unilateral, painful, blurry vision

- Myelitis: numbness and weakness in torso/extremities

Common relapse symptoms

7
New cards

The first clinical neurologic episode caused by CNS demyelination that lasts ≥ 24 hours and does not yet meet criteria for MS.

What is Clinically Isolated Syndrome (CIS)?

8
New cards

63%

Approximately what percentage of patients with CIS will progress to MS?

9
New cards

Relapsing-remitting multiple sclerosis (RRMS) [85%]

What is the most common form of MS at diagnosis?

10
New cards

Relapses of new or worsening neurologic symptoms followed by periods of recovery (remission)

How is RRMS clinically characterized?

11
New cards

Secondary Progressive Multiple Sclerosis (SPMS)

What occurs after RRMS, in which neurologic disability progressively worsens independent of relapses?

12
New cards

Because clinicians cannot predict exactly when progression begins and must identify it over time

Why is SPMS considered a retrospective diagnosis?

13
New cards

Progressive neurologic disability from disease onset, without relapses

What distinguishes Primary Progressive MS (PPMS) from other MS types?

14
New cards

Ocrelizumab (Ocrevus)

What is the only FDA-approved disease-modifying therapy for PPMS?

15
New cards

1. Visual complaints: unilateral vision loss (optic neuritis) or double vision

2. Spasticity

3. Gait problems, falls

4. Bowel and bladder dysfunction

5. Sexual dysfunction

6. Weakness, ataxia

7. Speech difficulty

8. Psychological changes

9. Cognitive changes

10. Fatigue

Primary symptoms of MS

16
New cards

1. Recurrent UTIs

2. Renal calculi

3. Decubiti and osteomyelitis

4. Osteoporosis

5. Respiratory infections

6. Poor nutrition

Secondary symptoms of MS

17
New cards

TCAs

- anticholinergic side effects, orthostatic hypotension, sedation

Which class of antidepressants should be avoided in most MS patients?

18
New cards

MRI

Gold standard for MS diagnosis

- also identifies lesions for treatment monitoring

19
New cards

Presence of lesions throughout the brain and spinal cord

What is dissemintation in space (DIS)?

20
New cards

Development of new lesions over time

What is dissemintation in time (DIT)?

21
New cards

Temporary worsening or recurrence of symptoms indicative of nerve inflammation from demyelination

- Must last at least 24 hours +/- recovery without fever or infection

What defines acute relapse in MS?

22
New cards

(in order of preference)

1. Methylprednisolone 500 - 1000 mg IV daily x 3-7 days

2. Prednisone 1250 mg PO daily x 3-7 days (heavy tablet burden)

3. Acthar Gel 80-120 units IM/SubQ daily x 7 days

- Directly stimulates the adrenal cortex to synthesize and release steroids

- Highly purified ER preparation of adrenocorticotropic hormone (ACTH)

- Inadequate or intolerable response to corticosteroids

4. Steroid refractory relapse: Plasma exchange daily x 3-7 days

Treatment for acute relapse

23
New cards

plasma exchange daily for 3-7 days

If a patient cannot tolerate or does not respond to steroids for the management of an acute relapse, what is used?

24
New cards

- Glatiramer acetate (Copaxone, Glatopa)

- Interferon beta-1a (Avonex, Rebif)

- Interferon beta-1b (Betaseron)

- PegINF beta-1b (Plegridy)

What are the platform therapies for MS?

- indicated for CIS, RRMS, SPMS

- good safety profile, but only modestly effective

- place in therapy: patient concern for safety/AEs and pregnancy

25
New cards

Glatiramer acetate (Copaxone, Glatopa) 20 mg SQ daily or 40 mg TIW

Platform therapy for MS that blocks T-cell-mediated myelin damage by acting as a decoy and mimicking the myelin sheath

- approved for CIS, RRMS, SPMS

- place in therapy: patient concern for safety/AEs and pregnancy

26
New cards

1. Interferon beta-1a

- Avonex 30 mcg IM weekly

- Rebif 22 mcg SQ TIW

2. Interferon beta-1b (Betaseron) 0.25 mg SQ QOD

3. PegINF beta-1b (Plegridy) 125 mcg SQ/IM every 2 weeks

Platform therapies for MS that inhibit T-cell activation and migration to the CNS

- approved for CIS, RRMS, SPMS

- place in therapy: patient concern for safety/AEs and pregnancy

27
New cards

Does not require laboratory monitoring

What is a major advantage of Glatiramer acetate (Copaxone, Glatopa)?

28
New cards

Lipoatrophy, vasodilation, injection site skin hardening

- counsel patients to rotate injection sites and to apply a cold compress to the injection site and take NSAIDs prior to administering

SEs of Glatiramer acetate (Copaxone, Glatopa)

29
New cards

- flu-like symptoms: HA, chills, myalgia, fever (usually transient; can counsel patient to take NSAID or Tylenol to reduce pain)

- worsening depression

- worsening HF

- increased LFTs

- increased seizure risk

- anemia, leukopenia, thrombocytopenia

SEs of the interferons

- Interferon beta-1a (Avonex, Rebif)

- Interferon beta-1b (Betaseron)

- PegINF beta-1b (Plegridy)

30
New cards

heart failure

Avoid interferons in patients with ____

31
New cards

Indicated for CIS, RRMS, SPM

- after Glatiramer/IFN due to injection fatigue

Place in therapy for Teriflunomide (Aubagio) 7 or 14 mg PO daily

32
New cards

A pyrimidine synthesis inhibitor that decreases CNS B and T lymphocytes

MOA of Teriflunomide (Aubagio)

33
New cards

1. Teratogenicity: if d/c, administer Cholestyramine for 11 days

2. Hepatotoxicity: monitor LFTs monthly

BBW for Teriflunomide (Aubagio)

34
New cards

men planning to father children

- if d/c, administer Cholestyramine for 11 days

Avoid Teriflunomide (Aubagio) in:

35
New cards

Hair thinning

Hepatotoxicity (monitor LFTs monthly)

SEs of Teriflunomide (Aubagio)

36
New cards

CIS, RRMS, SPMS oral therapy

- Fingolimod: highly active disease

Place in therapy for the Sphingosine 1-Phosphate (S1P) Receptor Modulators

37
New cards

Sequesters lymphocytes within lymph nodes and prevents migration into the CNS

MOA of the Sphingosine 1-Phosphate (S1P) Receptor Modulators

38
New cards

1. Fingolimod (Gilenya)

2. Ozanimod (Zeposia)

3. Ponesimod (Ponvory)

4. Siponimod (Mayzent)

all administered PO once daily

List the Sphingosine 1-Phosphate (S1P) Receptor Modulators

39
New cards

- Bradycardia

- QT prolongation

- Macular edema (baseline ophthalmologic exam)

AEs of the Sphingosine 1-Phosphate (S1P) Receptor Modulators

40
New cards

Ophthalmologic

Which baseline exam is required prior to starting a Sphingosine 1-Phosphate (S1P) Receptor Modulator?

41
New cards

1. MI in the past 6 months

2. Unstable angina

3. Class III/IV HF

4. Uncontrolled HTN

Contraindications for the Sphingosine 1-Phosphate (S1P) Receptor Modulators

42
New cards

EKG

____ monitoring for the first dose of Fingolimod (Gilenya) is recommended for ≥6 hours.

43
New cards

CYP2C9

Which genotype testing is needed for Siponimod (Mayzent)?

44
New cards

1. Class Ia and III antiarrhythmics

- Ia: Quinidine, Procainamide, Disopyramide

- III: Amiodarone, Sotalol, Dofetilide, Ibutilide

2. Agents that prolong QT: Macrolides, FQs, Ondansetron, Citalopram, Ziprasidone

3. Agents that slow HR: beta-blockers, non-DHP CCBs, Digoxin

4. Immunosuppressants

5. Live vaccines: MMR, Varicella, Flumist

6. Ketoconazole

Fingolimod (Gilenya) drug interactions

45
New cards

CIS, RRMS, SPMS oral therapy

- Dimethyl used in highly active disease

- slower dose titration schedule over two weeks

Place in therapy for fumarates

46
New cards

1. Dimethyl fumarate (Tecfidera)

2. Diroximel fumarate (Vumerity)

3. Monomethyl fumarate (Bafiertam)

- all PO twice daily with a slow titration schedule over 2 weeks

- administer with high-fat, high-protein, low-starch food

List the fumarates

47
New cards

1. flushing

2. GI symptoms: nausea, diarrhea, abdominal pain

SEs of the fumarates

48
New cards

Lower infection risk compared to high-efficacy therapies

Advantages of the fumarates

49
New cards

1. Administer with high-fat, high-protein, low-starch food

2. Take a non-enteric coated aspirin (≤325 mg) 30 min prior to decrease flushing

Administration counseling points for the fumarates

50
New cards

Monomethyl fumarate (Bafiertam)

Which fumarate has improved GI tolerability?

51
New cards

RRMS, SPMS in patients with highly active disease or those who have issues with nonadherence

Place in therapy for Cladribine (Mavenclad)

- Given as two yearly courses, with each year consisting of 2 treatment courses of 4-5 consecutive days

52
New cards

Impairs DNA synthesis, depleting B and T lymphocytes

MOA of Cladribine (Mavenclad)

53
New cards

men planning to father a child

Avoid Cladribine (Mavenclad) in:

54
New cards

1. URTI

2. Lymphopenia

3. Herpes zoster

AEs of Cladribine (Mavenclad)

55
New cards

Herpes zoster

Patients must be screened for ____ prior to starting Cladribine (Mavenclad)

56
New cards

Malignancy

Teratogenicity

BBW for Cladribine (Mavenclad)

57
New cards

Hepatitis, TB, HIV

Monitor for which infections while on Cladribine (Mavenclad)?

58
New cards

CIS, RRMS, SPMS for highly active disease

- minimizes infusion reactions

Place in therapy for Natalizumab (Tysabri) IV monthly

- only available through TOUCH REMS Program

59
New cards

Monoclonal antibody that binds alpha4 integrin to block T-cell migration into the CNS

MOA of Natalizumab (Tysabri)

60
New cards

Progressive multifocal leukoencephalopathy (PML) risk

- increased in patients with JCV (+) antibodies and use >2 years

- TOUCH REMS Program

- JCV serology every 6 months

BBW for Natalizumab (Tysabri)

61
New cards

HA, UTI, depression, diarrhea

SEs of Natalizumab (Tysabri)

62
New cards

every 6 months

How often should JCV antibody testing be performed while on Natalizumab (Tysabri)?

63
New cards

1. Ocrelizumab (Ocrevus) IV infusion every 6 months

2. Ofatumumab (Kesimpta) SQ monthly

3. Ublituximab (Briumvi) IV infusion every 6 months

Humanized monoclonal antibodies that bind to CD20, suppressing and depleting circulating B-cells.

64
New cards

CIS, RRMS, SPMS, [PPMS → Ocrelizumab ONLY]

- Monoclonal Abs are not first-line for MS

- Less PML risk and less frequent infusions

Place in therapy for the anti-CD20 monoclonal antibodies

65
New cards

Infusion reactions, URTI

SEs of the anti-CD20 monoclonal antibodies

66
New cards

1 hour

How long should patients be observed after Ocrelizumab (Ocrevus) infusion?

67
New cards

RRMS, SPMS in patients with an inadequate response to ≥2 DMTS or with highly active disease

- REMS Program

Place in therapy for Alemtuzumab (Lemtrada)

- Year 1: IV infusion x 5 days

- Year 2: IV infusion x 3 days

68
New cards

Monoclonal antibody that binds CD52 surface antigen on B and T cells, NK cells, and macrophages to prevent the downstream inflammatory cascade

MOA of Alemtuzumab (Lemtrada)

69
New cards

Infusion reactions, autoimmune diseases, malignancy

BBW of Alemtuzumab (Lemtrada)

70
New cards

1. Infections: HSV, HPV, TB

2. Malignancy: thyroid, melanoma

3. Autoimmune diseases: thyroid, immune thrombocytopenia

SEs of Alemtuzumab (Lemtrada)

71
New cards

Monthly

How often should labs be done when receiving Alemtuzumab (Lemtrada)?

72
New cards

Acyclovir

What is prescribed with Alemtuzumab (Lemtrada) for HSV prophylaxis?

73
New cards

Refractory RRMS and SPMS

- typically not prescribed due to AEs and there being better therapies available; most often utilized as an oncologic agent

Place in therapy for Mitoxantrone (Novantrone) IV infusion every 3 months (lifetime cumulative dose: 140 mg/m2)

74
New cards

Inhibits B and T cell and macrophage proliferation and impairs antigen presentation

MOA of Mitoxantrone (Novantrone)

75
New cards

Cardiotoxicity

BBW of Mitoxantrone (Novantrone)

76
New cards

n/v/d, leukopenia

SEs of Mitoxantrone (Novantrone)

77
New cards

PML is caused by reactivation of latent John Cunningham virus (JCV) in immunocompromised patients, particularly those on MS therapies that reduce immune surveillance in the CNS

What causes Progressive Multifocal Leukoencephalopathy (PML), who is at risk, and why does it occur in MS patients on certain DMTs?

78
New cards

Immediately discontinue the disease-modifying therapy and consider plasmapheresis to remove the offending drug.

What is the immediate management when PML is suspected in an MS patient?

79
New cards

Skin assessment

What baseline assessment is recommended before starting interferons?

80
New cards

TB, pregnancy

What baseline screenings are required before starting teriflunomide?

81
New cards

monthly

How often are liver function tests monitored with teriflunomide?

82
New cards

VZV IgG, ECG, and ophthalmologic exam

What baseline tests are required before initiating S1P receptor modulators?

83
New cards

VZV IgG, HIV, hepatitis B, hepatitis C, TB, and pregnancy

What baseline tests are required before starting cladribine?

84
New cards

JCV antibodies, HIV testing, and brain MRI

What baseline tests are required before initiating natalizumab?

85
New cards

VZV IgG, HIV, hepatitis B, hepatitis C, and TB screening

What baseline infection screening is required before alemtuzumab therapy?

86
New cards

Monthly CBC monitoring

What ongoing laboratory monitoring is required with alemtuzumab?

87
New cards

VZV IgG, HIV, hepatitis B, hepatitis C, and TB screening

What baseline screening is required before starting anti-CD20 monoclonal antibodies?

88
New cards

As frequently as monthly (Lemtrada) or every 6 months for 1-2 years.

How often may DMT monitoring occur after therapy initiation?